Aflibercept in branch retinal vein occlusion as second line therapy: clinical outcome 12 months after changing treatment from bevacizumab/ranibizumab—a pilot study

PURPOSE: To evaluate the effect of aflibercept (as second line therapy) on the clinical outcome in patients with chronic macular edema secondary to branch retinal vein occlusion (BRVO) insufficiently responding to prior treatment with bevacizumab and/or ranibizumab. METHODS: Ten eyes of ten patients...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Int J Retina Vitreous
Hlavní autoři: Wirth, Magdalena A., Becker, Matthias D., Graf, Nicole, Michels, Stephan
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2016
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5088487/
https://ncbi.nlm.nih.gov/pubmed/27847638
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40942-016-0045-8
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky